Replies to post #106524 on Biotech Values

[DewDiligence]

PFO closure didn’t prevent strokes in STJ trial that ran for nine (!) years:

http://www.bloomberg.com/news/2012-10-25/st-jude-device-to-close-heart-holes-fails-to-prevent-stroke.html

STJ picked up the AMPLATZER product in its 2010 acquisition of AGAM for $1.3B (#msg-55673504), and it’s reasonable to ask whether STJ ultimately obtained any value from that deal.

NMT Medical, another company pursuing the connection between PFO closure and stroke, went bankrupt in 2011 (#msg-62251315).